National Heart, Lung, and Blood Institute; Notice of Closed Meeting, 30967 [2021-12139]
Download as PDF
<![CDATA[
Federal Register / Vol. 86, No. 110 / Thursday, June 10, 2021 / Notices
Hurley at 240–669–5092 or
benjamin.hurley@nih.gov, and reference
E–076–2019.
Collaborative Research Opportunity:
The National Institute of Allergy and
Infectious Diseases is seeking statements
of capability or interest from parties
interested in collaborative research to
further develop, evaluate or
commercialize this invention. For
collaboration opportunities, please
contact Benjamin Hurley; (240) 669–
5092, benjamin.hurley@nih.gov.
Dated: June 2, 2021.
Surekha Vathyam,
Deputy Director, Technology Transfer and
Intellectual Property Office, National Institute
of Allergy and Infectious Diseases.
[FR Doc. 2021–12182 Filed 6–9–21; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood
Institute; Notice of Closed Meeting
khammond on DSKJM1Z7X2PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
NHLBI Career Development Awards—K99.
Date: July 14, 2021.
Time: 11:30 a.m. to 1:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6705
Rockledge Drive, Bethesda, MD 20817
(Virtual Meeting).
Contact Person: Lindsay M. Garvin, Ph.D.,
Scientific Review Officer, Office of Scientific
Review/DERA, National Heart, Lung, and
Blood Institute, National Institutes of Health,
6705 Rockledge Drive, Suite 208–Y,
Bethesda, MD 20892, (301) 827–7911,
lindsay.garvin@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
17:15 Jun 09, 2021
Jkt 253001
[FR Doc. 2021–12139 Filed 6–9–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Benjamin Hurley at 240–669–5092;
benjamin.hurley@nih.gov. Licensing
information may be obtained by
communicating with the Technology
Transfer and Intellectual Property
Office, National Institute of Allergy and
Infectious Diseases, 5601 Fishers Lane,
Rockville, MD 20852; tel. 301–496–
2644. A signed Confidential Disclosure
Agreement will be required to receive
copies of unpublished information
related to the invention.
SUPPLEMENTARY INFORMATION:
Technology description follows:
SUMMARY:
BILLING CODE 4140–01–P
VerDate Sep<11>2014
Dated: June 4, 2021.
David W. Freeman,
Program Analyst, Office of Federal Advisory
Committee Policy.
Producing Modified Vaccinia Ankara
(MVA) Virus With Continuous Cell
Lines: Modifications of Mammalian
Host Cells for Increasing MVA Vaccine
Production Yield
Description of Technology: Modified
vaccinia Ankara (MVA) is a well-known
and important platform for vaccine
development, and many MVA-based
vaccine trials are currently underway to
prevent a variety of microbial diseases.
While MVA shows promise as a vaccine
platform, wide-scale industry use of
MVA may be currently held back due to
MVA’s severe host-restriction, and the
fact that large bulks of culture cells are
presently required to produce enough
product for mass commercial use. At
present, the range of commonly-used
culture cells that can support high-titer
production of MVA is limited to chick
embryo fibroblast (CEF) cells.
PO 00000
Frm 00058
Fmt 4703
Sfmt 4703
30967
Unfortunately, the production of CEF
cells in bulk involves many slow and
inefficient manufacturing steps both
upstream and downstream. Therefore,
especially in the context of pandemic
preparedness, continuous cell lines that
allow for efficient, large-scale MVA
propagation would be beneficial.
There is a clear need for an expanded
range of cell lines that are easily
maintained in culture, and that allow
for the production of high titers of
infectious MVA virus. The present
invention provides methods of
modifying non-permissive cell lines in a
way that allows for production of MVA.
Scientists at NIAID have made a
breakthrough discovery by identifying
the mammalian Zinc finger antiviral
protein (ZAP) as a restriction factor that
inhibits MVA growth in mammalian
cells. They have demonstrated that ZAP
abrogation enhanced replication of the
MVA in a range of mammalian cells that
are normally non-permissive for MVA
replication. In particular, CRISPR/Cas9
inactivation of ZAP was shown to
produce stable cell lines capable of
supporting MVA replication.
Additionally, recombinant host cells
engineered to produce vaccinia virus
proteins C12L and C16L have been
shown to overcome the host range
inhibition of the MVA.
This technology is available for
licensing for commercial development
in accordance with 35 U.S.C. 209 and 37
CFR part 404, as well as for further
development and evaluation under a
research collaboration.
Potential Commercial Applications:
• Vaccine Development:
Recombinant continuous cell lines
useful for efficient, large-scale
production of MVA.
• May offer improved vaccine
production scaling-response times,
enhancing epidemic/pandemic
preparedness.
Competitive Advantages:
• Overcomes inefficiencies associated
with CEF production of MVA-based
vaccines.
Inventors: Bernard Moss, Linda Wyatt,
Chen Peng, Gilad Sivan, Shira
Glushakow-Smith, all of NIAID.
Publications:
Liu R, Mendez-Rios JD, Peng C, et al. SPI–
1 is a missing host-range factor required
for replication of the attenuated modified
vaccinia Ankara (MVA) vaccine vector in
human cells.; PLoS Pathog. 2019.
Peng C, Moss B. Repair of a previously
uncharacterized second host-range gene
contributes to full replication of
modified vaccinia virus Ankara (MVA)
in human cells. Proc Natl Acad Sci U S
A. 2020.
Peng, C, Wyatt, L, Glushakow-Smith, SG, Lal-
E:\FR\FM\10JNN1.SGM
10JNN1
]]>Agencies
[Federal Register Volume 86, Number 110 (Thursday, June 10, 2021)]
[Notices]
[Page 30967]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-12139]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood Institute; Notice of Closed
Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Heart, Lung, and Blood Institute
Special Emphasis Panel; NHLBI Career Development Awards--K99.
Date: July 14, 2021.
Time: 11:30 a.m. to 1:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6705 Rockledge Drive,
Bethesda, MD 20817 (Virtual Meeting).
Contact Person: Lindsay M. Garvin, Ph.D., Scientific Review
Officer, Office of Scientific Review/DERA, National Heart, Lung, and
Blood Institute, National Institutes of Health, 6705 Rockledge
Drive, Suite 208-Y, Bethesda, MD 20892, (301) 827-7911,
[email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.233,
National Center for Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839,
Blood Diseases and Resources Research, National Institutes of
Health, HHS)
Dated: June 4, 2021.
David W. Freeman,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2021-12139 Filed 6-9-21; 8:45 am]
BILLING CODE 4140-01-P
